developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagscancer

#cancer

All articles tagged with "cancer"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

cancer Articles | Developments Today

Gilead and Merck's latest trial success and flop

Gilead and Merck's Latest Trial Success and Flop: Biotech Roundup

Gilead and Merck had one successful trial and one failed trial.
AstraZeneca's oral GLP-1 pill showed positive Phase 2b results.
GSK acquired a cancer startup for $10.6 billion.
Other news: Regeneron's Eylea, Bluebird Bio gene therapy approval, FDA rejection.

DE

DT Editorial Team·Jun 10, 2026·via statnews.com

More in Health→

Alcohol study discarded by Trump officials is published in scientific journal

Suppressed Alcohol Study Linking Even Light Drinking to Health Risks Finally Published

A government-commissioned study on alcohol health risks, suppressed by Trump officials, has been published in JAMA Network Open.
The study finds that even one drink per day increases risks of cancer and cardiovascular disease.
The findings challenge current U.S. dietary guidelines that allow moderate drinking.
Public health experts praise the publication, while the alcohol industry criticizes it.

DE

DT Editorial Team·Jun 9, 2026·via statnews.com

More in Health→

Phase 1 trial points to early promise for IMA401 in solid tumors

Phase 1 trial points to early promise for IMA401 in solid tumors

IMA401 was tested in 61 patients with advanced solid tumors.
The maximum tolerated dose was not reached under the trial protocol.
Researchers set a recommended phase 2 dose of 1 mg to 2 mg every two weeks.
Common treatment-related side effects included low-grade cytokine release syndrome, lymphopenia, and neutropenia.

DE

DT Editorial Team·Jun 1, 2026·via nature.com

More in Health→

A standing ovation for RevMed, and caution for Akeso

Ultra-low dosing could widen access to expensive cancer care

STAT reports that ultra-low doses could expand access to costly cancer treatments.
The access implications are especially significant for poorer countries.
Dose strategy can affect affordability, supply and treatment capacity.
Adoption would depend on strong evidence that lower dosing preserves clinical benefit.

DE

DT Editorial Team·Jun 1, 2026·via statnews.com

More in Health→

Ultra-low doses could bring costly cancer treatments to more patients in poorer countries

Low-dose cancer therapy study points to access gains

STAT highlighted ultra-low-dose immunotherapy as a potential way to cut treatment costs.
The candidate frames the development around improved access in poorer countries.
The broader significance is economic as well as clinical.

DE

DT Editorial Team·May 31, 2026·via statnews.com

DE

DT Editorial Team·May 28, 2026·via nature.com

DE

DT Editorial Team·May 13, 2026·via medicalxpress.com

DE

DT Editorial Team·May 12, 2026·via nature.com

DE

DT Editorial Team·May 7, 2026·via livescience.com

DE

DT Editorial Team·May 5, 2026·via newscientist.com

DE

DT Editorial Team·May 4, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 30, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 29, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 16, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 14, 2026·via nature.com

DE

DT Editorial Team·Apr 13, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 12, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 9, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 1, 2026·via medicalxpress.com

DE

DT Editorial Team·Mar 27, 2026·via nature.com

More in Health→

Phase 2 trial reports strong signal for FGFR inhibitor in SDH-deficient GIST

Phase 2 trial reports strong signal for FGFR inhibitor in SDH-deficient GIST

Ten of 24 patients had partial responses in the phase 2 trial.
Median progression-free survival reached 31.0 months.
The drug targets an FGFR1-driven loop linked to SDH-loss biology.

More in Health→

Remission Antibodies Point to a New CAR T Strategy Against Acute Myeloid Leukemia

Researchers used antibodies from AML patients in long-term remission after bone marrow transplant to identify a new target.
The target, U5 snRNP200, appears on the surface of leukemia cells in about half of AML patients but is usually found inside the nucleus.
Engineered CAR T cells showed activity in animal models and appeared broadly effective against several other leukemia types.

More in Health→

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial - Nature Medicine

CRISPR-Edited Bone Marrow Transplant Strategy Shows Early Promise in High-Risk AML

A phase 1/2a trial tested a CRISPR-edited allogeneic transplant product lacking CD33 in high-risk AML and MDS.
All 30 treated patients achieved neutrophil engraftment by day 28, with a median time of 10 days.
Nineteen patients received gemtuzumab ozogamicin maintenance, which was tolerated up to the recommended phase 2 dose.

More in Health→

Illustration of pancreatic cancer in a human body.

AI Study Suggests Pancreatic Cancer May Be Detectable Years Earlier on Routine CT Scans

Researchers used an AI model to analyze nearly 2,000 CT scans that had previously been cleared as normal.
The system reportedly identified subtle pancreatic irregularities linked to tissue that later became tumor.
The study suggests pancreatic cancer might be detectable up to three years earlier than standard clinical discovery.

More in Science→

An X-ray of the woman

Biopsy May Have Triggered a Rare Cancer Remission in a Highly Unusual Case

A 59-year-old woman’s arm tumour disappeared before planned surgery.
The cancer was identified as aggressive myxofibrosarcoma by needle biopsy.
Doctors think the biopsy may have triggered an immune response against the tumour.
The report says only nine known cases of this type have followed the same pattern.

More in Science→

A Blood Test for Hard-to-Spot Testicular Cancers Moves Closer to the Clinic

A Mayo Clinic study describes a blood test that detected germ cell tumors with high accuracy in a 427-sample analysis.
The approach identified 23 of 24 cancers that standard blood markers missed.
Researchers also built a companion assay to distinguish between the two main testicular cancer types.

More in Health→

CAR T’s biggest weak point may be the patient’s own aging immune cells

Rutgers researchers linked CAR T underperformance to senescent CD8+ T cells used as starting material.
Higher senescence burdens reduced cell expansion under standard CAR T culture conditions.
Analysis of published lymphoma data found stronger senescence signatures were associated with higher failure risk.
The work suggests pre-manufacturing cell-quality screening could improve patient selection and product design.

More in Health→

Experimental red-blood-cell delivery system turns immune cells into cancer fighters inside the body

Researchers used engineered red blood cells to carry mRNA-loaded lipid nanoparticles.
The genetic payload is designed to reprogram myeloid immune cells into tumor-targeting cells inside the body.
The strategy could eventually reduce the time and cost associated with conventional CAR cell manufacturing.

More in Health→

Barrett’s Esophagus Emerges as Strongest Confirmed Precursor to Esophageal Adenocarcinoma

Scientists say Barrett’s esophagus is the strongest confirmed precursor to esophageal adenocarcinoma.
The finding could improve early detection of the most common form of esophageal cancer.
Clinical impact may depend on how screening and surveillance practices adapt.

More in Health→

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature Medicine

Phase 2 Trial Suggests Elraglusib Extends Survival in Metastatic Pancreatic Cancer

Phase 2 trial compared elraglusib plus gemcitabine/nab-paclitaxel against chemotherapy alone in untreated metastatic pancreatic cancer.
Median overall survival was 10.1 months with elraglusib versus 7.2 months for chemotherapy alone.
One-year survival reached 44.1% in the combination arm compared with 22.3% in the control arm.

More in Health→

Canada is projected to see 254,100 cancer cases in 2026, with four cancers leading the burden

Canada is projected to see 254,100 cancer cases in 2026.
Lung, breast, prostate, and colorectal cancers are expected to make up 47% of new diagnoses.
The research was published in CMAJ.

More in Health→

Study Links Newly Detected Adult Anemia to Higher Cancer Risk and Mortality

A population-based study linked anemia detected in adults with higher cancer risk.
The same study also found an association between anemia and higher mortality.
The findings suggest newly detected anemia may warrant closer clinical follow-up.

More in Health→

AI Beats Physicians on Completeness in Cancer Pathology Report Summaries, Study Says

A Northwestern Medicine study found AI models generated more complete summaries of complex cancer pathology reports than physicians.
The study tested six models from Meta, Google and DeepSeek.
The finding points to a near-term role for AI in clinician-support and documentation workflows rather than autonomous care.

More in Health→

Study Links Environmental Pesticide Exposure to Cancer Risk Through Biological Mechanisms

A new Nature Health paper reports a strong link between pesticide exposure and cancer risk.
The research combines environmental data with a national-level approach.
The study highlights biological mechanisms behind the observed risk.

More in Health→

Phase 1 Study Suggests In Vivo CAR-T Manufacturing Could Shorten the Path to Myeloma Treatment

Phase 1 Study Suggests In Vivo CAR-T Manufacturing Could Shorten the Path to Myeloma Treatment

A phase 1 study tested an anti-BCMA CAR-T approach generated inside the body rather than manufactured outside it.
Five heavily pretreated patients received a single intravenous infusion without leukapheresis, ex vivo manufacturing, or lymphodepleting chemotherapy.
Four of five patients had objective responses, including three stringent complete remissions.
All patients had grade 3 or higher adverse events, highlighting the therapy’s risks despite the simplified workflow.

More in Health→